Becotatug vedotin

• Description :

  Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162) . These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) [1].

• Product Name Alternative :

  MRG003

• UNSPSC :

  12352203

• Target :

  Antibody-Drug Conjugates (ADCs) ; EGFR

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer

• Purity :

  96.03

• Smiles :

  [Becotatugvedotin]

• Molecular Weight :

  149470 (average)

• References & Citations :

  [1]Qiu MZ, et al. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8 (7) :1042-1046.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported